Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET

Journal of Nuclear Medicine

Volumn 52, Issue 10, 2011, Pages 1541-1549

  Kurland, Brenda F ^a   Peterson, Lanell M ^b   Lee, Jean H ^b   Linden, Hannah M ^c   Schubert, Erin K ^b   Dunnwald, Lisa K ^b   Link, Jeanne M ^b   Krohn, Kenneth A ^b   Mankoff, David A ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

18F FES PET; Breast cancer; Estrogen receptor imaging; Heterogeneity

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CORRELATION COEFFICIENT; FEMALE; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR BINDING;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 80053509282     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.091439     Document Type: Article

References (26)

1. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14:2000-2011. (Pubitemid 26230100)
2. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584-2589. (Pubitemid 26300127)
3. Fisher B, Redmond CK, Fisher ER. Evolution of knowledge related to breast cancer heterogeneity: a 25-year retrospective. J Clin Oncol. 2008;26:2068-2071.
4. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21:1254-1261.
5. Allegra JC, Barlock A, Huff KK, Lippman ME. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer. 1980;45: 792-794. (Pubitemid 10174626)
6. Yoshida T, Eguchi H, Nakachi K, et al. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis. 2000;21:2193-2201. (Pubitemid 32049225)
7. Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol. 2006;24:3019-3025. (Pubitemid 46638935)
8. Douglas-Jones AG, Collett N,Morgan JM, Jasani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma. J Clin Pathol. 2001;54:951-955. (Pubitemid 34032891)
9. Barry WT, Kernagis DN, Dressman HK, et al. Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol. 2010;28:2198-2206.
10. Hoefnagel LD, Van de Vijver MJ, Van Slooten HJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12:R75.
11. Thompson AM, Jordan LB, Quinlan P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence in Tissues Study (BRITS). Breast Cancer Res. 2010;12:R92.
12. Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer. 1996;73:5-12. (Pubitemid 26026252)
13. Gomez-Fernandez C, Daneshbod Y, Nassiri M, Milikowski C, Alvarez C, Nadji M. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol. 2008; 130:879-882.
14. Wu JM, Fackler MJ, Halushka MK, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008;14:1938-1946. (Pubitemid 351551102)
15. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
16. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996; 2:933-939.
17. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803. (Pubitemid 32538187)
18. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799. (Pubitemid 46630578)
19. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56. (Pubitemid 29137739)
20. 18F]fluoroestradiol for breast cancer imaging. Nucl Med Biol. 1999;26: 473-479.
21. Peterson LM, Kurland BF, Link JM, et al. Factors influencing the uptake of 18FFluoroestradiol (FES) in patients with estrogen receptor positive (ER1) breast cancer. Nucl Med Biol. In press.
22. Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L. Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol. 1981;11:523-526. (Pubitemid 11150198)
23. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
24. Mankoff DA, Dehdashti F. Imaging tumor phenotype: 1 plus 1 is more than 2. J Nucl Med. 2009;50:1567-1569.
25. Thie JA, Hubner KF, Smith GT. The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors. J Nucl Med. 2000;41:1664-1672.
26. Wolfinger RD, Tobias R, Sall J. Computing Gaussian likelihoods and their derivatives for general linear mixed models. SIAM J Sci Comput. 1994;15:1294-1310.